NCT01434017

Brief Summary

Incidence of postoperative nausea and vomiting (PONV) in children after tonsillectomy with or without adenoidectomy may be as high as 75%. Several medications may prevent and treat PONV, such as steroids, antidopaminergic drugs and serotonin (5-HT3) antagonists. The objective of this study is to compare three prophylactic antiemetic treatments:

  • dexamethasone alone (250 mcg/kg)
  • dexamethasone (250 mcg/kg) + droperidol (10 mcg/kg)
  • dexamethasone (250 mcg/kg) + ondansetron (150 mcg/kg).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Nov 2008

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 14, 2011

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

February 27, 2014

Status Verified

February 1, 2014

Enrollment Period

4.6 years

First QC Date

September 13, 2011

Last Update Submit

February 26, 2014

Conditions

Keywords

PONVDexamethasoneDroperidolOndansetronTonsillectomy

Outcome Measures

Primary Outcomes (1)

  • Incidence of PONV after tonsillectomy with or without adenoidectomy

    48 hours

Secondary Outcomes (1)

  • Incidence of side effects (extrapyramidal syndrome, hemorrhage, somnolence, headaches)

    48 hours

Study Arms (3)

Dexamethasone

ACTIVE COMPARATOR

Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.

Drug: Dexamethasone

Dexamethasone and Droperidol

ACTIVE COMPARATOR

Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.

Drug: Dexamethasone and droperidol

Dexamethasone and Ondansetron

ACTIVE COMPARATOR

Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.

Drug: Dexamethasone and Ondansetron

Interventions

Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.

Dexamethasone

Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.

Dexamethasone and Droperidol

Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.

Dexamethasone and Ondansetron

Eligibility Criteria

Age2 Years - 10 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • children aged 2-10 y.
  • children ASA 1-2
  • weight \> 15 kg
  • tonsillectomy with or without adenoidectomy

You may not qualify if:

  • intravenous induction
  • contraindication to steroids
  • contraindication to antidopaminergic drugs
  • contraindication to serotoninergic antagonists
  • administration of steroids, antidopaminergic drugs, or serotoninergic antagonists in the 24 hours before the surgery
  • refusal of parents
  • no-french speaking parents

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire Vaudois and University of Lausanne

Lausanne, Canton of Vaud, 1011, Switzerland

Location

MeSH Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

DexamethasoneDroperidolOndansetron

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNauseaSigns and Symptoms, DigestiveSigns and SymptomsVomiting

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedButyrophenonesKetonesOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsImidazolesAzolesHeterocyclic Compounds, 1-RingCarbazolesIndolesHeterocyclic Compounds, 3-Ring

Study Officials

  • Eric Albrecht

    Centre Hospitalier Universitaire Vaudois

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

September 13, 2011

First Posted

September 14, 2011

Study Start

November 1, 2008

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

February 27, 2014

Record last verified: 2014-02

Locations